A new report shows the five-year survival rate for all cancers reached a historic 70%. About 2.1 million new cancer diagnoses ...

Because 13% survival is not enough, PanCAN has set a bold goal: Drive the five-year survival rate to 20% by 2030. We will do ...

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and begins in the cells lining the ...

Furthermore, a near-doubling of 12-month survival was also achieved with the elraglusib regimen vs GnP alone (44.4% vs 22.3%), and at 24 months, the survival rate was nearly 5 times higher in the ...

BullFrog AI's bfLEAP platform identified biomarkers linked to improved survival in pancreatic adenocarcinoma patients treated ...

More than 70% of people diagnosed with cancer in the United States now survive for five years or more, a milestone experts ...

Armistice Capital acquired more shares of ImmunityBio as EMA recommended ANKTIVA approval and Q3 2025 product revenue surged ...

ECOG performance status was found to capture only part of the patient experience in gastric/GEJ adenocarcinoma. Among patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma, those ...

SAN FRANCISCO -- Patients with colon cancer and comorbid obesity treated with GLP-1 receptor agonists had lower mortality and ...

New research presented at ASCO GI positions both agents as potent therapeutic options, with potential to redefine standard ...

Aggressive renal cell carcinoma cases are increasing among younger adults aged 20 to 39 years in the United States.